This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Curis (CRIS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Curis (CRIS) delivered earnings and revenue surprises of -19.41% and 15.73%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
What Makes Curis (CRIS) a New Buy Stock
by Zacks Equity Research
Curis (CRIS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Strength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength?
by Zacks Equity Research
Curis (CRIS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
2seventy bio, Inc. (TSVT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pharming Group N.V. Sponsored ADR (PHAR) Soars 14.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Pharming Group N.V. Sponsored ADR (PHAR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Curis (CRIS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Curis (CRIS) delivered earnings and revenue surprises of 0% and 14.35%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Curis (CRIS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Curis (CRIS) delivered earnings and revenue surprises of -9.09% and 7.57%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 0% and 5.10%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Curis (CRIS) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Curis (CRIS) delivered earnings and revenue surprises of 14.29% and 4.72%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Editas (EDIT) delivered earnings and revenue surprises of -4.76% and 43.33%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Curis (CRIS) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Curis (CRIS) delivered earnings and revenue surprises of 17.65% and 6.77%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Agenus (AGEN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agenus (AGEN) delivered earnings and revenue surprises of -5.56% and 14.69%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Curis (CRIS) Gets FDA Nod to Partly Resume Leukemia Study
by Zacks Equity Research
The FDA allows Curis (CRIS) to resume enrollment of additional patients in the monotherapy phase of the TakeAim Leukemia study on emavusertib in patients will acute myeloid leukemia and myelodysplastic syndrome. Shares down.
Curis (CRIS) Lymphoma Study's Clinical Hold Lifted, Shares Gain
by Zacks Equity Research
The FDA lifts partial clinical hold on Curis' (CRIS) phase I/II TakeAim lymphoma study investigating emavusertib in patients with B-cell malignancies. Shares surge.
Curis (CRIS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Curis (CRIS) delivered earnings and revenue surprises of 0% and 1.40%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Curis (CRIS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Curis (CRIS) delivered earnings and revenue surprises of -5.88% and 6.71%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Down 31.3% in 4 Weeks, Here's Why You Should You Buy the Dip in Curis (CRIS)
by Zacks Equity Research
Curis (CRIS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Voyager Therapeutics (VYGR) Moves 5.8% Higher: Will This Strength Last?
by Zacks Equity Research
Voyager Therapeutics (VYGR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Curis (CRIS) Down on FDA Partial Clinical Hold on Lymphoma Study
by Zacks Equity Research
The FDA places a partial clinical hold on Curis' (CRIS) phase I/II TakeAim lymphoma study investigating emavusertib in patients with B-cell malignancies. Shares fall.
Curis (CRIS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Curis (CRIS) delivered earnings and revenue surprises of -15.38% and 3.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exact Sciences (EXAS) delivered earnings and revenue surprises of -40.66% and 0.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Is the Options Market Predicting a Spike in Curis (CRIS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Curis (CRIS) stock based on the movements in the options market lately.
Curis (CRIS) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Curis (CRIS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is the Options Market Predicting a Spike in Curis (CRIS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Curis (CRIS) stock based on the movements in the options market lately.
Here's Why Curis (CRIS) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
Curis (CRIS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.